您的购物车当前为空
别名 Cgp-6809, Cgp6809
Cgp 6809 is a new methylnitrosoureido-sugar derivative that has been shown to be active against a broad spectrum of transplantable tumours in mice and rats. CGP 6809 is a promising new agent for clinical trials, especially for large bowel and epidermoid lung cancer.

Cgp 6809 is a new methylnitrosoureido-sugar derivative that has been shown to be active against a broad spectrum of transplantable tumours in mice and rats. CGP 6809 is a promising new agent for clinical trials, especially for large bowel and epidermoid lung cancer.
| 规格 | 价格 | 库存 | 数量 |
|---|---|---|---|
| 25 mg | ¥ 15,000 | 8-10周 | |
| 50 mg | ¥ 19,800 | 8-10周 | |
| 100 mg | ¥ 25,500 | 8-10周 |
| 产品描述 | Cgp 6809 is a new methylnitrosoureido-sugar derivative that has been shown to be active against a broad spectrum of transplantable tumours in mice and rats. CGP 6809 is a promising new agent for clinical trials, especially for large bowel and epidermoid lung cancer. |
| 别名 | Cgp-6809, Cgp6809 |
| 分子量 | 321.33 |
| 分子式 | C12H23N3O7 |
| CAS No. | 84069-38-5 |
| 密度 | no data available |
| 存储 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
评论内容